Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q01860
UPID:
PO5F1_HUMAN
Alternative names:
Octamer-binding protein 3; Octamer-binding protein 4; Octamer-binding transcription factor 3
Alternative UPACC:
Q01860; A6NCS1; A6NLL8; D2IYK4; P31359; Q15167; Q15168; Q16422; Q5STF3; Q5STF4
Background:
POU domain, class 5, transcription factor 1 (POU5F1), also known as Octamer-binding protein 3/4 and Octamer-binding transcription factor 3, plays a pivotal role in embryonic development and stem cell pluripotency. It binds to the octamer motif, forming a trimeric complex with SOX2 or SOX15, regulating genes like YES1, FGF4, UTF1, and ZFP206.
Therapeutic significance:
Understanding the role of POU domain, class 5, transcription factor 1 could open doors to potential therapeutic strategies.